Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

The market expects Moderna (MRNA) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

We just received data on a new analyst forecast for $MRNA. Dimple Gosai from B of A Securities set a price target of 25.0 for MRNA. To track analyst ratings and price ...

Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share.

The biotech's innovative qualities will come in handy. Long gone are the days when Moderna ( MRNA 2.66%) would generate over $18 billion in annual sales from its COVID-19 vaccine. Over the past couple ...

In the latest trading session, Moderna (MRNA) closed at $25.51, marking a +2.03% move from the previous day. This change outpaced the S&P 500's 0.48% gain on the day. On the other hand, the Dow ...

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know. What To Know: Tuesday’s rally was driven by the release of positive ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...